A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 586-592

  Shao, Jimin ^a,b   Zhou, Bingsen ^a   Di Bilio, Angel J ^c   Zhu, Lijun ^a,b   Wang, Tieli ^a   Qi, Christina ^a   Shih, Jennifer ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5,5 DIMETHYL 1 PYRROLINE 1 OXIDE; CATALASE; CELL DNA; DITHIOTHREITOL; FERRIC ION; FERROUS CHLORIDE; FERROUS ION; FREE RADICAL; HOLOENZYME; OXYGEN; REACTIVE OXYGEN METABOLITE; RIBONUCLEOTIDE REDUCTASE; SUPEROXIDE DISMUTASE; TETRAMER; TYROSINE;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA SYNTHESIS; DRUG ACTIVITY; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IN VITRO STUDY; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT; SPIN TRAPPING;

CELL LINE, TUMOR; CELL PROLIFERATION; FERROUS COMPOUNDS; HUMANS; PYRIDINES; REACTIVE OXYGEN SPECIES; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; THIOSEMICARBAZONES; TUMOR SUPPRESSOR PROTEINS;

EID: 33645473324     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0384     Document Type: Article

References (32)

1. Kolberg M, Strand KR, Graff P, Andersson KK. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 2004; 1699:1-34.
2. Stubbe J, van Der Donk WA. Protein radicals in enzyme catalysis. Chem Rev 1998;98:2661-2.
3. Shao J, Zhou B, Zhu L, et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 2004;64:1-6.
4. Shao J, Zhou B, Zhu L, et al. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochem Pharmacol 2005;69:627-34.
5. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-9.
6. Nakano K, Balint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000;19:4283-9.
7. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature 2000;404:24-5.
8. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003;34:440-5.
9. Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 2003;63:980-6.
10. Zhou B, Liu X, Mo X, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63:6583-94.
11. Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998;58:1650-3.
12. Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43-9.
13. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2002;2:437-48.
14. Cooperman BS. Oligopeptide inhibition of class I ribonucleotide reductases. Biopolymers 2003;71:117-31.
15. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22:9063-74.
16. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39:3-12.
17. Finch RA, Liu M, Grill SP, et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 2000;59:983-91.
18. Yen Y, Margolin K, Doroshow J, et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 2004;54:331-42.
19. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004;22:1553-63.
20. Barr D. A step-by-step procedure for spin-trapping the hydroxyl radical (http://www.bruker-biospin.com/brukerepr/pdf/Ohtrap.pdf). From the EPR Application Notes website of the Bruker biospin corporation (http://www.bruker-biospin.com/brukerepr/appnotes.htm).
21. Ueno I, Hoshino M, Maitani T, Kanegasaki S, Ueno Y. Luteoskyrin, an anthraquinoid hepatotoxin, and ascorbic acid generate hydroxyl radical in vitro in the presence of a trace amount of ferrous iron. Free Radic Res Commun 1993;19:S95-100.
22. Antholine W, Knight J, Whelan H, Petering DH. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol Pharmacol 1977;13: 89-98.
23. Preidecker PJ, Agrawal KC, Sartorelli AC, Moore EC. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor. Mol Pharmacol 1980; 18:507-12.
24. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004;286:R431-44.
25. Thelander L, Graslund A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J Biol Chem 1983;258:4063-6.
26. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9:402-14.
27. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005;5:102-12.
28. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: past, present, and future. Curr Med Chem 2003;10: 983-95.
29. Nyholm S, Thelander L, Graslund A. Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 1993;32:11569-74.
30. Xue L, Zhou B, Liu X, Clarke K, Yen Y. Human ribonucleotide reductase small subunits hRRM2 and p53R2 display different regulation of mitochondrial redox potential. Proc Am Assoc Cancer Res 2005;46:1129.
31. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 1996;271: 20291-9.
32. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993;268:26200-5.